Akebia Therapeutics, Inc.
Exchange: NASDAQ
Ticker: AKBA
Date of Filing: 03/14/2022
Court: New York Eastern District Court
Filing Deadline

05/13/2022

Akebia Therapeutics, Inc.

Akebia is a biopharmaceutical company that focuses on the development and commercialization of renal therapeutics for patients with kidney diseases. The Companys lead investigational product candidate is vadadustat, an oral therapy, which is in Phase 3 development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent (NDD) adult patients. Akebias Phase 3 clinical programs for vadadustat include, among others, the PRO2TECT program in NDD-CKD patients with anemia (the PRO2TECT Program). The PRO2TECT Programs primary safety endpoint was defined as non-inferiority of vadadustat versus darbepoetin alfa in time to first occurrence of major adverse cardiovascular events (MACE). The complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Companys business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) vadadustat was not as safe in treating NDD-CKD patients with anemia as Defendants had represented; (ii) as a result, Defendants overstated the PRO2TECT Programs clinical prospects; (iii) accordingly, Defendants also overstated vadadustats overall commercial and regulatory prospects; and (iv) as a result, the Companys public statements were materially false and misleading at all relevant times. On September 3, 2020, Akebia issued a press release announcing top-line results from the PRO2TECT Program, disclosing that [v]adadustat did not meet the primary safety endpoint of the PRO2TECT program, defined as non-inferiority of vadadustat versus darbepoetin alfa in time to first occurrence of [MACE.] On this news, Akebias common stock price fell $7.35 per share, or 73.5%, to close at $2.65 per share on September 3, 2020.


For More information as well as to join this case please contact Atara Twersky, Esq. at atara@twerskylawgroup.com or atwersky@aftlaw.com.  Atara is Principal at Twersky Law Group and Of counsel at AF&T law firm where she is director of Investor Services.  Atara focuses her practice on assisting her clients with increasing their investment portfolio recoveries and ensuring that their portfolios remain healthy and robust.  For more information on shareholder recoveries click here and to listen to Atara’s podcast with notable guests in the Pension fund Industry listen to Pension and Investments Podcast, on all matters related to your investment portfolio and more. For more information on  Atara and her legal work connected to shareholder protection click here.

DOCUMENTS


COMPLAINT

PLEASE READ THE COMPLAINT  DOCUMENT BEFORE SIGNING UP FOR THIS CASE.